羟丁酸钠治疗帕金森病日间过度嗜睡与睡眠障碍:随机临床试验
这项随机双盲安慰剂对照交叉2a期试验在苏黎世大学医院睡眠实验室开展,纳入12例伴日间过度嗜睡(ESS>10)的帕金森病患者,评估夜间羟丁酸钠的疗效与安全性。结果显示羟丁酸钠显著改善客观和主观日间嗜睡,并延长慢波睡眠,但2例出现新发阻塞性睡眠呼吸暂停、1例出现异态睡眠,需随访多导睡眠监测。
要点
- 羟丁酸钠可显著改善帕金森病患者的客观和主观日间嗜睡。
- 羟丁酸钠显著延长客观测量的慢波睡眠时长。
- 治疗期间需随访多导睡眠监测,警惕新发阻塞性睡眠呼吸暂停和异态睡眠。
核心结论
- 本研究为羟丁酸钠治疗帕金森病日间过度嗜睡和夜间睡眠障碍提供了I级证据。
- 羟丁酸钠总体耐受良好,但可诱导新发阻塞性睡眠呼吸暂停和异态睡眠,需特殊监测。
研究设计与样本
- 随机、双盲、安慰剂对照、交叉2a期研究,2015年1月9日至2017年2月24日在苏黎世大学医院睡眠实验室单中心开展。
- 18例帕金森病伴日间过度嗜睡(ESS>10)患者经睡眠实验室筛查,排除5例睡眠呼吸暂停和1例撤回知情者后,12例随机分配至治疗序列(羟丁酸钠后安慰剂或安慰剂后羟丁酸钠,比例1:1)。
- 1例因洗脱期无关不良事件脱落,11例完成研究;2例在羟丁酸钠治疗期间发生阻塞性睡眠呼吸暂停(其中1例为脱落者),符合方案分析n=10,意向性分析n=12。
- 干预为夜间睡前及2.5至4.0小时后服用羟丁酸钠或安慰剂,个体化滴定剂量3.0至9.0 g/晚,治疗6周,间隔2至4周洗脱期。
主要发现
- 在意向性分析人群12例(10男2女;平均[SD]年龄62[11.1]岁;病程8.4[4.6]年)中,羟丁酸钠显著改善客观日间嗜睡(平均睡眠潜伏期+2.9分钟;95%CI 2.1至3.8分钟;P=.002)。
- 羟丁酸钠显著改善主观日间嗜睡(ESS评分-4.2分;95%CI -5.3至-3.0分;P=.001),8例(67%)患者达到电生理定义的阳性治疗反应。
- 羟丁酸钠显著改善主观睡眠质量并延长客观测量的慢波睡眠时长(+72.7分钟;95%CI 55.7至89.7分钟;P<.001),符合方案分析中差异更明显。
- 羟丁酸钠在剂量调整下总体耐受良好(无治疗相关脱落),但诱导2例新发阻塞性睡眠呼吸暂停和1例异态睡眠(经多导睡眠监测发现),这些患者均未从羟丁酸钠治疗中获益。
关键数值与推荐
- 主要结局为多导睡眠图多次睡眠潜伏期试验测定的平均睡眠潜伏期变化。
- 次要结局包括ESS评分、帕金森病睡眠量表-2及多导睡眠图客观夜间睡眠变量。
- 羟丁酸钠个体化滴定剂量3.0至9.0 g/晚,治疗6周,洗脱期2至4周。
- 日间过度嗜睡入组标准为ESS评分>10。
临床怎么用
- 羟丁酸钠可考虑用于伴日间过度嗜睡和夜间睡眠障碍的帕金森病患者,但需个体化滴定剂量。
- 治疗期间应随访多导睡眠监测,以排除治疗相关的新发阻塞性睡眠呼吸暂停和异态睡眠。
- 需更大样本、更长治疗时长的随访试验验证疗效和安全性。
局限性
- 单中心、小样本(意向性分析12例,符合方案分析10例)研究。
- 2例在羟丁酸钠治疗期间发生阻塞性睡眠呼吸暂停,1例发生异态睡眠,均未从治疗中获益。
- 需更大样本和更长治疗时长的随访试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sleep-wake disorders are a common and debilitating nonmotor manifestation of Parkinson disease (PD), but treatment options are scarce. OBJECTIVE: To determine whether nocturnal administration of sodium oxybate, a first-line treatment in narcolepsy, is effective and safe for excessive daytime sleepiness (EDS) and disturbed nighttime sleep in patients with PD. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, crossover phase 2a study carried out between January 9, 2015, and February 24, 2017. In a single-center study in the sleep laboratory at the University Hospital Zurich, Zurich, Switzerland, 18 patients with PD and EDS (Epworth Sleepiness Scale [ESS] score >10) were screened in the sleep laboratory. Five patients were excluded owing to the polysomnographic diagnosis of sleep apnea and 1 patient withdrew consent. Thus, 12 patients were randomized to a treatment sequence (sodium oxybate followed by placebo or placebo followed by sodium oxybate, ratio 1:1) and, after dropout of 1 patient owing to an unrelated adverse event during the washout period, 11 patients completed the study. Two patients developed obstructive sleep apnea during sodium oxybate treatment (1 was the dropout) and were excluded from the per-protocol analysis (n = 10) but included in the intention-to-treat analysis (n = 12). INTERVENTIONS: Nocturnal sodium oxybate and placebo taken at bedtime and 2.5 to 4.0 hours later with an individually titrated dose between 3.0 and 9.0 g per night for 6 weeks with a 2- to 4-week washout period interposed. MAIN OUTCOMES AND MEASURES: Primary outcome measure was change of objective EDS as electrophysiologically measured by mean sleep latency in the Multiple Sleep Latency Test. Secondary outcome measures included change of subjective EDS (ESS), sleep quality (Parkinson Disease Sleep Scale-2), and objective variables of nighttime sleep (polysomnography). RESULTS: Among 12 patients in the intention-to-treat population (10 men, 2 women; mean [SD] age, 62 [11.1] years; disease duration, 8.4 [4.6] years), sodium oxybate substantially improved EDS as measured objectively (mean sleep latency, +2.9 minutes; 95% CI, 2.1 to 3.8 minutes; P = .002) and subjectively (ESS score, -4.2 points ; 95% CI, -5.3 to -3.0 points; P = .001). Thereby, 8 (67%) patients exhibited an electrophysiologically defined positive treatment response. Moreover, sodium oxybate significantly enhanced subjective sleep quality and objectively measured slow-wave sleep duration (+72.7 minutes; 95% CI, 55.7 to 89.7 minutes; P < .001). Differences were more pronounced in the per-protocol analysis. Sodium oxybate was generally well tolerated under dose adjustments (no treatment-related dropouts), but it induced de novo obstructive sleep apnea in 2 patients and parasomnia in 1 patient, as detected by polysomnography, all of whom did not benefit from sodium oxybate treatment. CONCLUSIONS AND RELEVANCE: This study provides class I evidence for the efficacy of sodium oxybate in treating EDS and nocturnal sleep disturbance in patients with PD. Special monitoring with follow-up polysomnography is necessary to rule out treatment-related complications and larger follow-up trials with longer treatment durations are warranted for validation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02111122.
引用
- Büchele F, Hackius M, Schreglmann SR, et al. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29114733. doi:10.1001/jamaneurol.2017.3171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。